



US009234038B2

(12) **United States Patent**
Jung et al.

(10) **Patent No.:** **US 9,234,038 B2**
(45) **Date of Patent:** **Jan. 12, 2016**

(54) **COMPOSITIONS AND METHOD FOR THE
DIAGNOSIS, PREVENTION AND
TREATMENT OF ALZHEIMER'S DISEASE**

(75) Inventors: **Yong-Keun Jung**, Seoul (KR); **Sungmin Song**, Seoul (KR)

(73) Assignee: **Seoul National University Industry Foundation**, Seoul (KR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1030 days.

(21) Appl. No.: **13/353,574**

(22) Filed: **Jan. 19, 2012**

(65) **Prior Publication Data**

US 2012/0114669 A1 May 10, 2012

Related U.S. Application Data

(62) Division of application No. 11/947,612, filed on Nov. 29, 2007, now Pat. No. 8,124,358.

(30) **Foreign Application Priority Data**

Nov. 9, 2007 (KR) 10-2007-114468

(51) **Int. Cl.**

A61K 38/08 (2006.01)
A61K 38/04 (2006.01)
A61K 38/17 (2006.01)
C07K 7/06 (2006.01)
C07K 16/28 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/283** (2013.01); **A61K 38/04** (2013.01); **A61K 38/08** (2013.01); **A61K 38/1716** (2013.01); **A61K 38/1774** (2013.01); **C07K 7/06** (2013.01); **G01N 2333/4709** (2013.01); **G01N 2800/2821** (2013.01)

(58) **Field of Classification Search**

CPC ... **A61K 38/04**; **A61K 38/08**; **A61K 38/1716**; **A61K 38/1774**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2002/0061515 A1 5/2002 Lynch et al.
2004/0185045 A1 9/2004 Koenig et al.
2004/0248766 A1 12/2004 LeBlanc
2008/0014141 A1 1/2008 Huber et al.

OTHER PUBLICATIONS

Banks WA (2006) The CNS as a target for peptides and peptide-based drugs. *Expert Opin. Drug Deliv.* 3(6):707-712.*
Geylis V et al. (2005) Human monoclonal antibodies against amyloid-beta from healthy adults. *Neurobiol. Aging*, 26:597-606.*
Morgan D (2006) Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. *Neurochem. Intl.* 49:190-194.*
Nakamura A & Takai T (2004) A role of FcγRIIb in the development of collagen-induced arthritis. *Biomed. Pharmacotherap.* 58:292-298.*
Szabo P et al. (2008) Natural human antibodies to amyloid beta peptide. *Autoimmun. Rev.* 7:415-420.*
Arancio et al., "Rage potentiates Aβ induced perturbation of neuronal function in transgenic mice," *The EMBO Journal*, 23:4096-4105, 2004.
Gyllys et al., "Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-β protein into synaptic terminals," *Journal of Neurochemistry*, 84:1442-1451, 2003.
Lustbader et al., "ABAD Directly Links Aβ to Mitochondrial Toxicity in Alzheimer's Disease," *Science*, 304:448-452, 2004.
Nakamura et al., "A role of FcγRIIb in the development of collagen-induced arthritis," *Biomedicine & Pharmacotherapy*, 58:292-298, 2004.
Saavedra et al., "Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E," *Journal of Biological Chemistry*, 282(49):35722-35732, 2007.
Takuma et al., "ABAD enhances Aβ-induced cell stress via mitochondrial dysfunction," *The FASEB Journal*, 19:597-598, 2005.

* cited by examiner

Primary Examiner — Kimberly A. Ballard

(74) *Attorney, Agent, or Firm* — Klarquist Sparkman, LLP

(57) **ABSTRACT**

Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-β (Aβ) to FcγRIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, an FcγRIIb-specific peptide and an FcγRIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of Aβ and the neurotoxicity, neuronal cell death and memory impairment mediated by Aβ by inhibiting the binding between Aβ and FcγRIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.

1 Claim, 13 Drawing Sheets

Fig. 1




Fig. 2





Fig. 3

a.



b.




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10

			SEQ.ID.NO.
a.	#1: DAEFRHDSG	WT	19
	#2: DAAFRHDSG	(EA)	20
	#3: DAEARHDSG	(FA)	21
	#4: DAEFAHDSG	A β (1-9) (RA)	22
	#5: DAEFRADSG	(HA)	23
	#6: DAEFRHASG	(DA)	24
	#7: DAEARHASG	(FDAA)	25
	#8: QLVFLEG	(95-101)	26
	#9: RCHSWRNK	mFc γ R11b (107-114)	27
	#10: RCHSARNK	(107-114)(WA)	28




Fig. 11




Fig. 12





Fig. 13



COMPOSITIONS AND METHOD FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional of U.S. patent application Ser. No. 11/947,612, filed Nov. 29, 2007, now U.S. Pat. No. 8,124,358, issued Feb. 28, 2012, which claims the benefit of Korea Patent Application No. KR 10-2007-114468, filed Nov. 9, 2007, both of which are incorporated by reference herein.

SEQUENCE LISTING

The Sequence Listing is submitted as an ASCII text file named Sequence_Listing.txt, which was created on Jan. 10, 2012, and is 15,449 bytes, which is incorporated by reference herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid- β to Fc γ RIIb, and a method of screening the inhibitor. More particularly, the present invention relates to methods of diagnosing, preventing and treating Alzheimer's disease using an inhibitor of the binding between amyloid- β and Fc γ RIIb, which is selected from the group consisting of an Fc γ RIIb protein or a variant thereof, an Fc γ RIIb extracellular domain, an anti-Fc γ RIIb antibody, a specific peptide and an Fc γ RIIb-specific siRNA, and a method of screening the inhibitor.

2. Description of the Related Art

About 50-70% of all people having dementia suffer from Alzheimer's disease (hereinafter, referred to simply as "AD"), which is caused by the progressive degeneration of nerve cells in the brain, resulting in the loss of cognitive ability. AD is divided into two forms: familial AD, which has genetic links and runs in families, and sporadic AD, which develops in many people for no obvious reason. AD patients typically have multiple cognitive deficiencies, which are manifested by memory impairment and psychological symptoms such as psychosomatic abnormalities, including increased anxiety and hypersensitivity.

Two pathological hallmarks are seen in the brains of patients who die of AD: senile plaques and neurofibrillary tangles. Senile plaques are extracellular accumulations of proteins and dead cells, and are primarily composed of amyloid- β (A β) peptides (Hardy, J. et al., *Nat. Neurosci.* 1:355-358, 1998). The progressive loss of cognitive ability, which is the major pathological feature of AD patients, seems to be caused by the aberrant deposition of A β .

A β is produced from amyloid precursor protein (APP) through proteolytic cleavage. APP is cleaved by β -secretase (BACE) and γ -secretase, yielding A β (Craven, R., *Nat. Rev. Neurosci.* 2: 533, 2001; David, H. S. et al., *Nat. Rev. Neurosci.* 2: 595-598, 2001; Yankner, B. A., *Neuron* 16: 921-932, 1996; Selkoe, D. J., *Nature* 399: A23-A31, 1999).

Studies associated with AD to date resulted in the development of preventive and therapeutic agents for AD mainly using agents inhibiting A β production, such as secretase inhibitors, or inhibitors of neurotoxicity, such as antioxidants. Current medications for AD include nicotinic receptor agonists, such as ABT-418; muscarinic receptor agonists, such as Xanomeline and YM-976; acetylcholine precursors, such as

lecithin and acetyl-L-carnitine; metal chelators, such as desferrioxamine and clioquinol; beta-sheet breakers, such as iA β 5 and iA β 11; antioxidants, such as vitamin E, *Ginkgo biloba*, melatonin and idebenone; sAPP releasing agents, such as nicotine, acetylcholine and carbachol; β -secretase or γ -secretase inhibitors, such as OM99-1, OM99-2, OM99-3 and Z-VLL-CHO; non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and indomethacin; hormones such as estrogen; vaccines, such as AN-1792; and cholesterol-lowering agents, such as simvastatin and atorvastatin. However, most medications are only marginally helpful in slightly relieving the pathological symptoms of AD or slowing AD progression, or are difficult to apply in practice due to their toxicity. Thus, there remains an urgent need for the development of stable and effective drugs for AD treatment.

Recent AD-associated studies have been focused on the identification of neurotoxic mechanisms of A β . Pro-apoptotic genes, such as prostate apoptosis response-4 (Par-4), tau protein kinase 1 (GSK-3 β), Calsenilin/DREAM/KChIP3, and cell death-promoting gene 5 (DP5), are shown to be overexpressed or their activities are increased in neuronal cells cultured in the presence of A β or neuronal cells from AD patients. The blocking of the functions of the proteins reduces A β -induced neuronal death (Guo, Q. et al., *Nat. Med.* 4:597-562, 1998; Takashima, A. et al., *Proc. Natl. Acad. Sci. USA* 90:7789-7793, 1993; Jo, D. G. et al., *FASEB J.* 15:589-591, 2001; Imaizumi, K. et al., *J. Biol. Chem.* 274:7975-7981, 1999). However, these reports are not sufficient to identify an intracellular signaling pathway for A β -induced neuronal toxicity so as to develop AD drugs for preventing A β -induced neuronal loss. To date, inhibitors of A β -induced neurotoxicity have not been found even in vitro.

An important step to define neurotoxic mechanisms of A β is to find a receptor for A β on neuronal cells. Many efforts have been made, but no specific receptor for A β has been identified yet. Several proteins interacting with A β , including receptors for advanced glycation end-product (RAGE) (Arancio, O. et al., *EMBO J.* 23:4096-4105, 2004) and amyloid-beta binding alcohol dehydrogenase (ABAD) (Takuma, K. et al., *FASEB J.* 19:597-598, 2005), were reported to be receptors for A β . However, such proteins have been shown to serve as cellular cofactors, rather than functioning to fundamentally modulate signal transduction in neuronal cells or neuronal toxicity. Thus, they are not likely to be receptors for A β . This is because they were identified not using a knock-out method but through the observation that their overexpression increases signal transduction and neuronal toxicity.

On the other hand, Fc γ receptor IIb (Fc γ RIIb), expressed on immune cells, has been known to be a receptor having low binding affinity to immunoglobulin G. Individuals having a mutation in the Fc γ RIIb gene (Fc γ RIIb[I232T]), leading to abnormal immune responses, are susceptible to autoimmune diseases. Also, the Fc γ RIIb receptor has recently been known to play a regulatory role in arthritis (Nakamura, A. et al., *Biomed. Pharmacother.* 58:292-298, 2004). However, the involvement of Fc γ RIIb in dementia and its potential as a therapeutic target for dementia have not been known.

The inventors of this application found for the first time that Fc γ RIIb serves as a receptor for A β as well as playing an immunoregulatory role. In particular, the present inventors found that Fc γ RIIb acts as a protein mediating A β neurotoxicity and serves as a receptor in an A β -initiated toxic signaling pathway, through which Fc γ RIIb binds A β as the first event of the toxic signaling in neuronal cells and transduces the cell death signal into the cells. The present inventors also found that Fc γ RIIb enhances A β deposition, associated with memory impairment in AD, within neuronal cells. Based on

these findings, the present inventors further found that an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, an FcγRIIb-specific peptide and an FcγRIIb-specific siRNA suppress neuronal cell death and prevent memory loss in subjects, thereby leading to the present invention.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide an inhibitor for the binding of Aβ to FcγRIIb.

It is another object of the present invention to provide a method of screening an inhibitor for the binding of Aβ to FcγRIIb.

It is a further object of the present invention to provide a diagnostic method and a diagnostic kit for Alzheimer's disease.

It is yet another object of the present invention to provide a method of preventing and treating Alzheimer's disease.

In order to accomplish the above objects, the present invention provides a method of preventing and treating Alzheimer's disease by inhibiting the binding of Aβ to FcγRIIb.

The present invention also provides an inhibitor for the binding of Aβ to FcγRIIb. The inhibitor includes an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, an FcγRIIb-specific peptide, and an FcγRIIb-specific siRNA.

The present invention further provides a method of screening an agent inhibiting the interaction between Aβ and FcγRIIb. The screening method includes screening an agent inhibiting the activity of FcγRIIb, an agent suppressing the expression of FcγRIIb, an agent inhibiting the transduction of the toxic signal of Aβ into neuronal cells through FcγRIIb, and an agent inhibiting the interaction between Aβ and FcγRIIb.

The present invention still further provides a method of diagnosing Alzheimer's disease comprising determining the expression level of FcγRIIb.

The present invention still further provides a kit for diagnosing Alzheimer's disease comprising determining the expression level of FcγRIIb.

The present invention still further provides a method of preventing and treating Alzheimer's disease based on the use of the method of inhibiting the interaction between Aβ and FcγRIIb.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

FIG. 1 shows the FcγRIIb expression, increased upon exposure to Aβ₁₋₄₂, which was detected using RT-PCR (a), Western blotting (b) and immunostaining (c) (Aβ: Aβ₁₋₄₂; Bapta: Bapta-AM; Calp.: Calpeptin; Asc.: Ascorbic acid; Tuni: tunicamycin);

FIG. 2 shows neuronal cell death induced by overexpression of FcγRIIb and an FcγRIIb mutant;

FIG. 3 shows the inhibition of neuronal cell death using a siRNA against FcγRIIb and a siRNA against RAGE (b), wherein the expression of each protein was detected using Western blotting (a) (pSuper-Neo: void vector; siFcγRIIb #1: siRNA-expressing cell line #1; siFcγRIIb #2: siRNA-expressing cell line #2; siRAGE #1: siRNA-expressing cell line #1; siRAGE #2: siRNA-expressing cell line #2);

FIG. 4 shows the increased survival of Aβ-exposed cells when treated with an FcγRIIb extracellular domain (ED) (b), wherein the expression of each protein was detected using Western blotting (a) (Extra-FcγRIIb: FcγRIIb-ED);

FIG. 5 shows the results of immunohistochemical analysis for FcγRIIb expression levels in the brains of Tg2576 mice (a) and AD patients (b);

FIG. 6 shows the results of immunostaining for intracellular accumulation of Aβ₁₋₄₂ in siFcγRIIb-transfected cells;

FIG. 7 shows the results of an in vitro binding assay between FcγRIIb and Aβ₁₋₄₂ (T: trimer; D: dimer; M: monomer);

FIG. 8 shows the schematic structure of an FcγRIIb-CD40 chimeric protein (a), and the stimulation of NF-κB activation when Aβ₁₋₄₂ binds FcγRIIb (b);

FIG. 9 showed the predicted binding site structure of Aβ₁₋₄₂ and FcγRIIb;

FIG. 10 shows the sequences of peptides inhibiting the binding between Aβ₁₋₄₂ and FcγRIIb (a) and the inhibition degree of the binding inhibitory peptides (b);

FIG. 11 shows the effects of the peptides inhibiting the binding between Aβ₁₋₄₂ and FcγRIIb on Aβ-induced neurotoxicity;

FIG. 12 shows the inhibitory effects of the peptides inhibiting the binding between Aβ₁₋₄₂ and FcγRIIb on memory decline (a and b: Y-maze test; c and d: passive avoidance test); and

FIG. 13 shows the results of immunostaining for intraneuronal accumulation of Aβ₁₋₄₂ in neurons treated with peptides inhibiting the binding between Aβ₁₋₄₂ and FcγRIIb.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The terms used herein will have the following meanings.

The term "peptide" refers to a molecule in which two or more amino acids are linked via peptide bonds. The peptide can be synthesized through chemical synthesis, and also can be generated using typical genetic recombination technology.

The term "siRNA" refers to a RNA molecule that binds to a specific sequence in cells and thus knocks out a target gene. The siRNA can be prepared through the chemical synthesis of RNA oligonucleotides, small RNA synthesis using in vitro transcription, digestion of long dsRNA synthesized by in vitro transcription with RNase III or Dicer, expression from a siRNA expression plasmid or viral vector in cells, and expression from a PCR-derived siRNA expression cassette in cells.

The term "variant" refers to a peptide in which one or more amino acids, excluding amino acids critical in exerting its function, have been replaced, but which retains its innate function.

The term "interaction inhibitor" refers to a substance that inhibits interactions between proteins. The inhibitor is intended to indicate a composition including proteins, antibodies and peptides inhibiting the association between proteins, or an expression inhibitor.

The term "expression inhibitor" refers to a substance that suppresses the transcription or translation of a target gene, and is intended to indicate a composition including molecules commonly used for expression suppression, such as siRNAs or antisense nucleotides, which have a sequence complementary to a target gene.

The term "control group" refers to a test group that is treated with a buffer alone, used for dissolving a compound to be tested, or a test group that is treated with a compound known not to affect the function of a protein to be tested.

The term "FcγRIIb chimeric protein" refers to a chimeric (or fusion) protein of FcγRIIb with an effector protein (a protein activating the expression, color development or color change of a specific protein or cellular signal transduction upon the interaction between FcγRIIb and Aβ).

Hereinafter, the present invention will be described in detail.

I. The present invention provides a method of preventing and treating AD by inhibiting the binding of Aβ to FcγRIIb.

The inventors of this application identified a receptor for Aβ, which is the major pathological cause of AD, on neuronal cells, and, based on this finding, developed a method of preventing and treating AD by inhibiting the association between Aβ and FcγRIIb. The expression of FcγRIIb was found to increase in neuronal cells exposed to Aβ (FIG. 1). Then, a FcγRIIb wild type and a FcγRIIb variant were prepared and administered to neuronal cells along with Aβ. As a result, cells treated with the FcγRIIb variant were found to exhibit reduced cell death rates (FIG. 2). These results indicate that FcγRIIb mediates Aβ signaling.

The present inventors prepared siRNAs to suppress the transcription of FcγRIIb and RAGE, which is known to be a cell surface receptor for Aβ (panel a, FIG. 3). The transcriptional suppression of RAGE expression did not result in any increase in cell survival, whereas all cells survived when the transcription of FcγRIIb was suppressed (panel b, FIG. 3). These results indicate that FcγRIIb rather than RAGE is the direct cell surface protein for Aβ signaling.

Then, an FcγRIIb extracellular domain was prepared, and neuronal cells exposed to Aβ were treated with this extracellular domain and examined for cell survival rates. The increased expression of FcγRIIb due to exposure to Aβ was suppressed (panel a, FIG. 4), and the relative cell viability was increased to that of cells not exposed to Aβ (panel b, FIG. 4). These results indicated that the FcγRIIb-mediated neuronal transduction of Aβ signaling was inhibited.

The in vivo distribution of Aβ and FcγRIIb was examined. Oligomeric Aβ and FcγRIIb were found to be co-localized in the brain tissue of Tg2576 mice (AD animal model), indicating that both of them are present in the same region (FIG. 5a). Also, Aβ was expressed together with FcγRIIb in brain specimens from AD patients, confirming that both of them are present in the same cells (FIG. 5b). The transcriptional suppression of RAGE expression did not result in a decrease in the intracellular accumulation of Aβ, whereas the transcriptional suppression of FcγRIIb expression markedly reduced intracellular Aβ accumulation (FIG. 6). These results indicate that FcγRIIb is involved in the intracellular accumulation of Aβ as well as in intracellular signal transduction of Aβ.

Based on the above results, the binding between Aβ and FcγRIIb was examined in vitro. The in vitro experiment revealed that Aβ binds to FcγRIIb (FIGS. 7 and 8).

In addition, the inventors of this application identified for the first time the structure of Aβ bound to FcγRIIb using a computer program. Researchers made many efforts to determine the structure of Aβ, but failed to crystallize Aβ. Aβ is difficult to crystallize because it is present as amorphous aggregates, called amyloid plaques, in AD patients. However, recently, increasing evidence suggests that such Aβ aggregates are not directly involved in neuronal cell death, and that soluble oligomers of Aβ play a major role in neuronal toxicity. Recently, the three-dimensional structure of Aβ oligomers was determined by simulating the stable oligomerization of Aβ monomers using in silico methods (Urbanc, B. et al., Proc. Natl. Acad. Sci. U.S.A. 101, 17345-17350, 2004). The present inventors predicted the FcγRIIb-bound structure of Aβ using the known three-dimensional structures of Aβ

and FcγRIIb. This predicted structure showed that the structures of Aβ and FcγRIIb precisely fit together (FIG. 9). Aβ binds to an extracellular domain of FcγRIIb. Aβ is present in oligomeric forms, in which hydrophilic N-terminal regions are flexible and C-terminal regions aggregate to form an oligomer. The present inventors found that extended N-terminal regions bind FcγRIIb to exert cytotoxicity using an affinity program (Insight II, Acelrys Co.).

When primary cultured neuronal cells from the cerebral cortex of rats were exposed to Aβ and treated with either IgG or IgA, Aβ neurotoxicity was blocked only in cultures treated with IgG, indicating that the Aβ binding site of FcγRIIb is identical to that for IgG. The co-crystal structure of Fcγ receptor IIb, which has a structure similar to FcγRIIb, with IgG shows that a tryptophan pocket (Trp87 and Trp110) of FcγRIIb interacts with a praline residue at 329 (Pro329) of IgG (Sondermann P. et al., Nature. 2000 Jul. 20; 406(6793): 267-273). As well, a peptide containing a tryptophan pocket of FcγRIIb has been shown to inhibit the binding between IgG and FcγRIIb (Goldsmith, E. B. et al., Biochemistry. 1997 Jan. 28; 36(4):952-959). Thus, the present inventors predicted the binding IgG and FcγRIIb also occurs in a tryptophan pocket (Trp92 and Trp115) and replaced two tryptophan residues (Trp92 and Trp115) of an FcγRIIb-CD40 chimeric protein with alanine. This replacement reduced NF-κ B activation. The present inventors conducted an in silico simulation based on the above results. This simulation showed that a phenylalanine residue at position 4 of Aβ makes a strong hydrophobic interaction with two tryptophan residues, Trp92 and Trp115, of FcγRIIb, an aspartate residue at position 7 of Aβ makes a strong hydrophilic interaction with two lysine residues, Lys116 and Lys118, of FcγRIIb, a glutamine residue at position 3 of Aβ makes a relatively weak interaction with Tyr165 of FcγRIIb, and Arg5 and His6 residues of Aβ rarely interact with residues of FcγRIIb.

Based on the structure of Aβ bound to FcγRIIb, the present inventors prepared peptides capable of inhibiting the binding between Aβ and FcγRIIb. The peptides were found to effectively inhibit the binding between Aβ and FcγRIIb (FIGS. 10 and 11).

The peptides were injected into the brain of mice, and the memory ability of mice was assessed. As a result, memory impairment, as seen in AD cases, was remarkably restored (FIG. 12). Also, the mice treated with the peptide inhibitors displayed no accumulation of the full length Aβ₁₋₄₂ peptide in the brain (FIG. 13).

II. The present invention provides interaction inhibitors inhibiting the interaction between Aβ and FcγRIIb.

The interaction inhibitors may be selected from the group consisting of an FcγRIIb protein or a variant thereof, an FcγRIIb extracellular domain, an anti-FcγRIIb antibody, a peptide inhibiting the binding between Aβ and FcγRIIb, and an FcγRIIb expression inhibitor including an FcγRIIb-specific siRNA or an FcγRIIb-specific antisense nucleotide.

i) FcγRIIb Protein or Variant Thereof.

An FcγRIIb protein or a variant thereof competes with endogenous FcγRIIb in neuronal cells for Aβ binding to inhibit the binding of Aβ to endogenous FcγRIIb. Thus, a cell death signal of Aβ is not transduced into neuronal cells, thus preventing cell death.

The FcγRIIb protein has the nucleotide sequence of SEQ ID No. 30 and the amino acid sequence of SEQ ID No. 31, and variants thereof are also available. In a preferred embodiment, an FcγRIIb variant is prepared by replacing an isoleucine residue at 232 of human FcγRIIb with threonine, and has the sequence of SEQ ID No. 32. The variant is not specifically limited thereto, and any variant in which other residues of

FcγRIIb are mutated and which is able to modulate the signal transduction mediated by FcγRIIb is available. In a preferred embodiment, when an FcγRIIb variant was prepared and introduced into neuronal cells, Aβ-induced neuronal cell death decreased (FIG. 2).

ii) FcγRIIb Extracellular Domain

FcγRIIb is composed of an extracellular domain and an intracellular domain, and the extracellular domain binds to Aβ. Thus, the extracellular domain also competes with endogenous FcγRIIb in neuronal cells for Aβ binding to thus inhibit the binding of Aβ to endogenous FcγRIIb, thereby inhibiting neuronal cell death.

The FcγRIIb extracellular domain may be any one derived from humans, mice, rats, or the like. Preferred is a human-derived extracellular domain of FcγRIIb. Also, the FcγRIIb extracellular domain may be produced using a method known to those skilled in the art, for example, through cloning into *E. coli*, mass production and purification, or through gene introduction into animal cells or other eukaryotic cells (yeast or insect cells) and purification. In the practice of the present invention, the FcγRIIb extracellular domain is purified using a method described in Sondermann P. et al., 1999 Mar. 1; 18(5):1095-1103. The FcγRIIb extracellular domain was found to increase the relative viability of neuronal cells exposed to Aβ to the same level as cells not exposed to Aβ (FIG. 4).

iii) Anti-FcγRIIb Antibody

An anti-FcγRIIb antibody, prepared using the entire region or extracellular domain of FcγRIIb as an antigen, competes with Aβ for FcγRIIb binding and thus inhibits the binding of Aβ to FcγRIIb in neuronal cells.

iv) Interaction Inhibitory Peptide

An interaction inhibitory peptides was prepared in order to inhibit the binding between Aβ and FcγRIIb. The peptide is designed based on an amino acid sequence predicted as a binding site of Aβ to FcγRIIb or vice versa (see FIG. 9), but is not limited thereto. Preferably, the peptide is a peptide or a mutant thereof, which consists of one to nine amino acids comprising phenylalanine at position 4 of SEQ ID No. 19, corresponding to the N-terminal region of Aβ. Also, preferably, the peptide is an amino acid, a peptide or a mutant thereof, which consists of one to nine amino acids, comprising tryptophan at position 5 of SEQ ID No. 27, spanning from position 107 to 114 of the amino acid sequence of FcγRIIb. In a preferred embodiment, peptides were designed to have sequences represented by SEQ ID Nos. 19 to 28, but are not limited thereto. When the specific peptides were incubated with FcγRIIb-CD40 chimera and Aβ, specific peptides #1, #4 and #9 effectively inhibited the binding between FcγRIIb-CD40 and Aβ (FIG. 10). When neuronal cells were treated with the peptides and Aβ, cells exhibited increased survival (FIG. 11). Also, the peptides were injected along with Aβ into the brains of mice, and mice were assessed for memory ability. Peptides #1 and #9 were found to restore Aβ-induced memory decline (FIG. 12). The immunohistochemical analysis of the brain of experimental animals showed that peptide #1 completely inhibited intracellular accumulation of Aβ in neuronal cells (FIG. 13).

v) FcγRIIb Expression Inhibitor

The term "FcγRIIb expression inhibitor" refers collectively to substances that specifically inhibit the transcriptional or translational expression of FcγRIIb, and may include siRNAs, antisense nucleotides and compounds.

FcγRIIb siRNAs are not limited to specific sequences, and any siRNA sequence capable of inhibiting the binding between Aβ and FcγRIIb by suppressing the expression of FcγRIIb may be used. In an embodiment, an FcγRIIb-specific

siRNA consists of sense and antisense sequences, which are represented by SEQ ID Nos. 11 and 12. Sense and antisense sequences are suitably annealed and inserted into a pSuper-neo vector (Oligoengine, USA). A siRNA expression vector useful in the present invention is not specifically limited, but is preferably prepared by introducing a nucleotide sequence corresponding to the siRNA into a commonly used siRNA expression vector, psiRNA (Invitrogen, USA), pRNA (GenScript, USA), psLentGene (USA), pSIREN (Clontech, USA), pU6shX (Vector CoreA, Korea), pSilencer (aobion, USA), or pSuper-neo (Loigoengine, USA). The vector may be introduced into the nucleus of cells in the form of pure plasmid DNA or a complex with a transfection reagent or a target delivery substance, or in the form of a recombinant virus vector. Suitable viral vectors for use in the present invention include adenovirus, adeno-associated virus, and retrovirus including lentivirus. When the constructed vector was transfected into neuronal cells, it reduced Aβ-induced neuronal cell death (panel b, FIG. 3) and effectively inhibited intracellular Aβ (FIG. 6).

Antisense nucleotides have been approved as drugs having potential for therapeutic application to various human diseases. According to the Watson-Crick base pairing rules, a nucleotide is annealed to (hybridized with) a complementary sequence of DNA, immature mRNA or mRNA to interrupt the transmission of genetic information. The specificity of antisense nucleotides to target sequences makes them exceptionally multi-functional. An antisense-nucleotide is a long chain of monomer units and thus can be readily synthesized to correspond to a target RNA sequence. Many reports have recently demonstrated the usefulness of antisense nucleotides as a biochemical tool in the study of target proteins (Rothenberg et al., *J. Natl. Cancer Inst.*, 81:1539-1544, 1999). Many advances have been recently made in the fields of oligonucleotide chemistry and the synthesis of nucleotides having improved cell adhesion, target binding affinity and resistance to nucleases, suggesting that antisense nucleotides may be used in novel therapeutic approaches. For example, an antisense oligonucleotide targeting cmyb has been used to completely eliminate myelogenous leukemia cells from the bone marrow of patients suffering from myelogenous leukemia (Gewirtz and Calabreta, U.S. Pat. No. 5,098,890). Antisense nucleotides are known to have in vivo therapeutic efficacy on cytomegalovirus retinitis. Antisense nucleotides to FcγRIIb are not limited to specific sequences, but any antisense nucleotides inhibiting the binding between Aβ and FcγRIIb by suppressing the expression of FcγRIIb may be used.

III. The present invention provides a pharmaceutical composition for preventing or treating AD comprising the interaction inhibitor as an effective ingredient.

The present composition includes the effective ingredient in an amount of 0.0001 to 50 wt % based on the total weight of the composition.

In addition to the interaction inhibitor, the present composition may include one or more effective ingredients exhibiting functions that are the same as or similar to the interaction inhibitor.

The present composition may also include, in addition to the aforementioned effective ingredients, one or more pharmaceutically acceptable carriers for administration. The pharmaceutically acceptable carrier may include saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes and mixtures of two or more thereof. If desired, the composition may further include other typical additives, such as antioxidants, buffers, and bacteriostatics. Also, diluents, dispersing agents, surfactants, binders and lubricants may be further

added so as to be formulated into injectable formulations, such as solutions, suspensions and emulsions, pills, capsules, granules or tablets. The carrier may be conjugated to a target site-specific antibody or other ligands so as to act specifically in the target site. Further, the composition may be desirably formulated according to each disease or ingredient using a proper method in the art or the method described in Remington's Pharmaceutical Science (updated version, Mack Publishing Company, Easton Pa.).

The pharmaceutical composition of the present invention, although not limited thereto, is administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or locally). The dosage may vary depending on the patient's weight, age, gender, health state and diet, administration time, administration mode, excretion rate, and severity of illness. The daily dosage ranges from about 0.01 to 12.5 mg/kg, and preferably from 1.25 to 2.5 mg/kg. The daily dosage may be taken as a single dose or divided into several doses.

IV. The present invention provides a method of screening a substance inhibiting the binding between A β and Fc γ RIIb, Fc γ RIIb-mediated signal transduction, or the intracellular translocation of A β and Fc γ RIIb.

i) The Present Invention Provides a Method of Screening an Inhibitor of the Interaction Between A β and Fc γ RIIb.

The screening method includes the steps of 1) adding a compound to be tested before, after or during the binding between all or part of Fc γ RIIb and all or part of A β ; 2) measuring the binding degree between Fc γ RIIb and A β ; and 3) determining whether the compound reduces the binding between A β and Fc γ RIIb in comparison with a control. At step 1), the entire Fc γ RIIb protein may have the sequence of SEQ ID No. 31, and the partial portion of Fc γ RIIb may be an Fc γ RIIb extracellular region which is represented by SEQ ID No. 33. The entire A β protein may have the sequence of SEQ ID No. 29, and the partial portion of A β may be an N-terminal region of A β . The screening may be carried out using various methods analyzing protein-protein interaction, which are known to those skilled in the art. Such methods for analyzing the association between proteins include yeast two-hybrid system (Parda et al., *Epub*, 85:347-355, 2005), immunoprecipitation (IPP), Biocore™, Fluorescence Energy Transfer (FRET), and GST-full down assay (Lee SY, *Biochem Biophys Res Commun*, 334:1445-1451, 2005), but the present invention is not limited thereto, and any known methods for analyzing the association between proteins may be used.

ii) The Present Invention Provides a Method of Screening an Inhibitor of Fc γ RIIb.

The screening method includes the steps of 1) contacting all or part of Fc γ RIIb with a compound to be tested; 2) measuring the binding degree of the compound to Fc γ RIIb; and 3) determining whether the compound has high binding affinity to Fc γ RIIb in comparison with a control. At step 1), the entire Fc γ RIIb protein may have the sequence of SEQ ID No. 31, and the partial portion of Fc γ RIIb may be an Fc γ RIIb extracellular region, which is represented by SEQ ID No. 33. The screening may be carried out using various methods analyzing protein-compound interaction, which are known to those skilled in the art. Such methods include MALDI-TOF, but the present invention is not limited thereto, and any known methods for analyzing the association between a protein and a compound may be used.

iii) The Present Invention Provides a Method of Screening a Substance Inhibiting the Expression of Fc γ RIIb.

The screening method includes the steps of 1) treating a brain cell culture with a compound to be tested; 2) measuring the expression level of Fc γ RIIb in the brain cell culture; and 3)

determining whether the compound inhibits Fc γ RIIb expression in comparison with a control. At step 1), B103 cells or primary neuronal cells from the cerebral cortex may be used, but the present invention is not limited thereto, and any known cell lines expressing Fc γ RIIb may be used. The Fc γ RIIb expression may be assessed using RT-PCR, an immunoassay, and the like, but the present invention is not limited thereto, and any known methods for measuring the amount of a transcript or a protein translated therefrom may be used.

iv) The Present Invention Provides a Method of Screening a Substance Inhibiting the Intracellular Translocation of A β and Fc γ RIIb.

The screening method includes the steps of 1) treating a brain cell culture with A β and a compound to be tested; 2) detecting the intracellular level of A β in the brain cell culture; and 3) determining whether the compound inhibits the intracellular translocation of A β in comparison with a control. At step 1), B103 cells or primary neuronal cells from the cerebral cortex may be used, but the present invention is not limited thereto and any known cell lines expressing Fc γ RIIb may be used. The intracellular translocation of A β may be assessed using antibodies, compounds and peptides binding specifically to A β or Fc γ RIIb. Also, A β and Fc γ RIIb may be detected using a protein conjugated to a fluorescent, colorimetric or radioactive protein, compound or peptide. Thus, A β and Fc γ RIIb may be detected using fluorescence detection, radioactive detection and colorimetric detection apparatuses.

v) The Present Invention Provides a Method of Screening a Substance Inhibiting the Interaction Between A β and Fc γ RIIb Using an Fc γ RIIb Chimeric Protein.

The screening method includes the steps of 1) treating a cell line expressing an Fc γ RIIb chimeric protein with A β and a compound to be tested; 2) measuring the activity of the Fc γ RIIb chimeric protein; and 3) determining whether the compound inhibits the activity of the chimeric protein in comparison with a control. At step 1), the Fc γ RIIb chimeric protein is a receptor, and any protein capable of measuring the force of interaction between A β and Fc γ RIIb, as determined through the expression, color development or color change thereof, or the cellular signal transduction mediated thereby, may be fused to Fc γ RIIb. The Fc γ RIIb chimeric protein may be created by linking Fc γ RIIb to a specific protein, of which the expression, color development, color change or cellular signal transduction is stimulated upon the interaction between Fc γ RIIb and A β . In a preferred embodiment, CD-40, activating cellular signal transduction, was linked to Fc γ RIIb. In the present invention, the transmembrane protein CD-40 mediating intracellular signal transduction was used, but a protein such as TRK, which contains both a transmembrane domain and a cytoplasmic domain, is preferred. However, the present invention is not limited thereto.

vi) The Present Invention Provides a Method of Screening a Substance Inhibiting the Interaction Between A β and Fc γ RIIb Using a Software Program.

The screening method includes the steps of 1) inputting information about the structure of a compound to be tested into a software program; and 2) determining whether the compound inhibits the binding between A β and Fc γ RIIb using the software program. The software program useful in the method may be selected from the group consisting of DOCK™, FlexX™, and Affinity™. The present inventors employed an Affinity Program (InsightII, Accelrys Inc.). A compound inhibiting A β -Fc γ RIIb interaction may be determined based on 1) the protein structure of Fc γ RIIb, containing amino acids corresponding to glutamic acid at position 64, tryptophan at 132, tryptophan at 155, lysine at 156 and lysine at 158 of SEQ ID No. 31, and 2) the protein structure of

11

A β , containing amino acids corresponding to glutamic acid at position 3, phenylalanine at 4, histidine at 6 and aspartic acid at 7 of SEQ ID No. 29.

V. The present invention provides a method of diagnosing Alzheimer's disease by measuring the expression level of Fc γ RIIb.

The expression level of Fc γ RIIb may be detected using any known methods capable of measuring the expression level of the Fc γ RIIb protein. Examples of such methods include, but are not limited to, an immunoassay with an antibody binding specifically to Fc γ RIIb, and RT-PCR and Northern blotting with nucleic acid molecules capable of complementarily binding to the Fc γ RIIb gene.

X. The present invention provides a kit for diagnosing Alzheimer's disease by measuring the expression level of Fc γ RIIb. The diagnostic kit may include DNA, RNA and a protein, binding specifically to Fc γ RIIb, a buffer, a standard antibody, a secondary antibody labeled with an enzyme catalyzing a colorimetric reaction or a fluorescent substance, and a substance for color development. Also, when a compound binding specifically to Fc γ RIIb is used, this compound is used in a form in which it is conjugated to a fluorescent or colorimetric label, which may be visually detected.

The present invention also provides a method of diagnosing Alzheimer's disease using the diagnostic kit. The method includes the steps of 1) collecting a specimen from a subject; 2) reacting the specimen with a substance binding specifically to Fc γ RIIb and washing the specimen; and 3) measuring the amount of the specifically bound substance. At step 3), when an antibody specific to Fc γ RIIb is used, the antibody is allowed to react with a secondary antibody conjugated to a fluorescent substance, is washed, and is analyzed using a fluorescence microscope or scanner. When a compound specific to Fc γ RIIb is used, the bound compound may be quantified in a bound or separated state.

A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as the limit of the present invention.

EXAMPLE 1

Gene Expression Profiling Using DNA Microarray

Neuronal cells were isolated from the cerebral cortex of 16 day-old rat embryos and cultured. The primary-cultured cortical neuronal cells were exposed to 5 μ M of A β (500 μ M in PBS; Sigma, USA) for 24 hrs. Total RNA was isolated from the cells using TRIZOL Reagent (GIBCO-BRL, USA) according to the manufacturer's protocol. Gene expression was analyzed using DNA microarray filters (GF300, GF301, GF302, Invitrogen, USA) containing 17,000 rat cDNAs according to the manufacturer's instruction. Results obtained from three independent experiments were statistically analyzed using the Pathway3TM software program (ResgenTM, Invitrogen, USA).

As a result, the expression of Fc γ RIIb exhibited a 2.740.5-fold increase compared to control DNA spots (consisting of total genomic DNA). Through this DNA microarray analysis, the increased expression of E2-25K/Hip-2 and changes in the expression of other proteins of the ubiquitin/proteasome system were previously reported (Song et al., *Molecular cell*, 12(3), 553-563, 2003).

12

EXAMPLE 2

Detection of Changes in Fc γ RIIb Expression Upon Exposure to A β

2-1: Reverse Transcription Polymerase Chain Reaction (RT-PCR)

The primary neuronal cells from the rat cerebral cortex were exposed to 5 μ M of A β for 48 hrs. Cells were harvested, and total RNA for reverse transcription was isolated using TRIZOLR Reagent (Invitrogen, USA). cDNAs were synthesized through reverse transcription, which was carried out using 5 μ g of total RNA and ImProm-IITM Reverse Transcriptase (Promega, USA) according to the manufacturer's protocol. RT-PCR was performed using the following primers: Fc γ RIIb-5'-EcoRI primer (5'-CGCGGAATTCGATG-GACAGCAACAGGACT-3': SEQ ID No. 1), primer (5'-CGGGTACCATAATGIGGITCTGGTAGTC-3': SEQ ID No. 2), Fc γ RI-RT-5' primer (5'-TTGGTGAACACAGTTCTC-TATGTGAAAATACACAGGCTGC-3': SEQ ID No. 3), Fc γ RI-RT-3' primer (5'-CTATCTTACAGTGGCTGTACT-TCTTCATACACGTCATCGCT-3': SEQ ID No. 4), Fc γ RIIa-RT-5' primer (5'-GCCGATTICTGCCTAGTGATGTGC-CTCCTGITTGCAGTGG-3': SEQ ID No. 5), and Fc γ RIIa-RT-3' primer (5'-TCATTTGTCTGTGGAGCCTC-TTCCGACTGACAGGGATC-3': SEQ ID No. 6). Hactin was used as an internal control, and was amplified with the Hactin sense primer (5'-GCGTCCACCCGCGAG-3': SEQ ID No. 7) and the Hactin anti-sense primer (5'-TATAG-CAGGGTCAAC-3': SEQ ID No. 8). PCR was carried out in a total volume of 50 μ l using one-fifth of the reverse transcription reaction solution as a template. PCR conditions included denaturation at 95° C. for 5 min, and 10, 15, 20 or 25 cycles of denaturation at 95° C. for 60 sec, annealing at 56° C. for 60 sec and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 7 min.

The exposure of B103 cells to A β resulted in a specific increase of Fc γ RIIb expression (panel a, FIG. 1). These results were consistent with those of the DNA microarray analysis in Example 1.

2-2. Western Blot Analysis

Rat B103 neuronal cells were treated with a calcium chelator (BAPTA-AM, 5 μ M; EGTA, 1 mM), a calpain protease inhibitor (calpeptin, 10 μ M), and an antioxidant (ascorbic acid, 5 μ M) for 2 hrs, and exposed to A β for 48 hrs. Then, cells were lysed with a sampling buffer (10% glycerol, 2% SDS, 62.5 mM Tris-HCl, 2% β -mercaptoethanol, pH 6.8). The cell lysates were separated on a 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, and transferred onto a nitrocellulose membrane. Western blotting was performed with the primary antibody, monoclonal K9.631 (a gift from Dr. Hammerling, Memorial Sloan Kettering Cancer Center, NY) and goat anti-mouse IgG antibody-conjugated horseradish peroxidase as a secondary antibody (Santa Cruz Biotechnology, USA). A control was incubated with anti- α -tubulin antibody (T5168) (Sigma, USA) and the same HRP-conjugated secondary antibody.

The Western blotting showed that the A β -induced Fc γ RIIb expression was not suppressed upon treatment with the calcium chelators, calpain protease inhibitor and antioxidant (panel, FIG. 1). Thus, the A β -induced Fc γ RIIb expression seems to occur in a specific manner. Also, the Fc γ RIIb expression increased even upon the blocking of the action of calcium and active oxygen species, which mediate the toxic signaling of A β , indicating that A β acts upstream of A β signaling to induce Fc γ RIIb expression.

13

2-3. Immunostaining

As described in Example 2-1, B103 cells were exposed to PBS, tunicamycin (Tuni), which inhibits N-glycosylation as post-translational modification of proteins, and A β for 48 hrs. Cells were fixed, probed with the primary antibody monoclonal K9.631 (Memorial Sloan Kettering Cancer Center, NY), and observed under a fluorescence microscope (Leica DMRBE, Germany). This test was carried out as described in Song et al., *Molecular cell*, 12(3), 553-563, 2003.

When B103 cells were exposed to A β , the expression of Fc γ RIIb increased (panel c, FIG. 1). These results were consistent with those of the DNA microarray analysis in Example 1.

EXAMPLE 3

Evaluation of Cell Death Upon Fc γ RIIb
Overexpression and Inhibition of A β Neurotoxicity
Using Fc γ RIIb Mutant

An Fc γ RIIb expression vector and an Fc γ RIIb mutant expression vector were constructed and transfected into rat neuronal B103 cells. The expression vectors were prepared as follows. The rat Fc γ RIIb gene was amplified by performing PCR using a rat brain cDNA library (Invitrogen, USA) as a template with a set of Fc γ RIIb-5'-EcoRI primer (5'-CGCG-GAATTCGATGGACAGCAACAGGACT-3'; SEQ ID No. 1) and Fc γ RIIb-3'-KpnI primer (5'-CGGGTACCATAATGTG-GTTCTGGTAGTC-3'; SEQ ID No. 2). PCR was carried out in a total volume of 100 μ l using 20 pmol of each primer. PCR conditions included denaturation at 95° C. for 5 min, and 30 cycles of denaturation at 95° C. for 60 sec, annealing at 56° C. for 60 sec and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 7 min. The amplified rat Fc γ RIIb gene was inserted into pEGFP-N1 (Clontech, USA), and the resulting vector was designated "pFc γ RIIb". An Fc γ RIIb (1232T) mutant was prepared through PCR using Fc γ RIIb [1232T]-5' primer (5'-GCTGTCGCTGGAAGTGTAGCT-GCC-3'; SEQ ID No. 9) and Fc γ RIIb [1232T]-3' primer (5'-GGCAGCTACAGCAGTTCCAGCGACAGC-3'; SEQ ID No. 10).

PCR was carried out in a total volume of 50 μ l using 10 pmol of each primer. PCR conditions included denaturation at 95° C. for 5 min, and 30 cycles of denaturation at 95° C. for 5 min, annealing at 56° C. for 60 sec and extension at 72° C. for 10 sec, followed by final extension at 72° C. for 30 min. The amplified rat Fc γ RIIb[1232T] mutant gene was inserted into pEGFP-N1 (Clontech, USA), and the resulting vector was designated "pFc γ RIIb[1232T]". This vector was digested with DpnI, and the excised mutant gene was subjected to DNA sequencing, which was performed by the COSMO Company (Korea). Then, B103 cells were transfected with 300 ng of pEGFP, 900 ng of pcDNA3 (void vector), 900 ng of pFc γ RIIb, and 900 ng of pFc γ RIIb[1232T] using lipofectamine (Invitrogen, USA) according to the manufacturer's instructions. Cells were then exposed to 5 μ M of A β and phosphate buffered saline (PBS) for 48 hrs. Cell viability was estimated under a fluorescence microscope based on the morphology of green fluorescent protein (GFP)-positive cells (expressing GFP through pEGFP introduction).

Fc γ RIIb-overexpressing B103 cells exhibited increased cell death, whereas neuronal cell death was inhibited in B103 cells transfected with the Fc γ RIIb mutant expression vector (FIG. 2). These results indicate that A β signaling occurs via Fc γ RIIb, and that an Fc γ RIIb mutant is useful to inhibit the toxic signaling of A13.

14

EXAMPLE 4

Construction of siRNAs Specific to Fc γ RIIb and
RAGE

Small interfering RNAs (siRNAs) inhibiting the expression of Fc γ RIIb and receptors for advanced glycation end-product (RAGE), which is known as a cell surface receptor of A β , were constructed, and their effects on cell death were compared to each other. A siRNA duplex was formed by hybridizing sense and antisense complementary RNA oligonucleotides, listed in Table 1, below, and was inserted into pSuper-neo (Oligoengine, USA). The siRNA expression vectors thus constructed were individually transfected into B103 cells using lipofectamine (Invitrogen, USA) according to the manufacturer's protocol. The resulting transfected cells were designated "pSuper-neo", "psiFc γ RIIb#1", "psiFc γ RIIb#2", "psiRAGE#1", and "psiRAGE#2". Then, transfected cells were subjected to Western blot analysis. Western blotting was performed as described in Example 2-2 with anti-Fc γ RIIb antibody (primary antibody: K9.361; secondary antibody: goat anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)), anti-RAGE antibody (primary antibody: Sc8230 (Santa Cruz Biotechnology, USA); secondary antibody: donkey anti-goat IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)), and anti- α -tubulin antibody (primary antibody: T5168 (Sigma, USA); secondary antibody: goat anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)). As a result, siRNAs were found to completely suppress the expression of Fc γ RIIb and RAGE (panel a, FIG. 3). Then, the transformed B103 cells were exposed to 5 μ M of A β or PBS for 48 hrs, and their viability was evaluated. Cell survival was assessed through trypan blue exclusion, Hoechst staining (Sigma, USA), and Annexin V labeling (Promega, USA). The survival of effector cells and cells introduced with pEGFP (Clontech, USA) was determined by observing the morphology of GFP-positive cells under a fluorescence microscope (Leica DMRBE, Germany). Cells were determined to be dead when the cell morphology changed to a spherical shape and the cell membrane was disrupted or destroyed.

Cell death was blocked in cells transfected with a siRNA against Fc γ RIIb. In contrast, cells transfected with a siRNA against RAGE, which is known to be a receptor of A β , exhibited low survival (panel b, FIG. 3). That is, a siRNA against RAGE, which is known as a target for inhibiting A β signaling, was found to have a poor inhibitory effect on neuronal cell death, whereas the silencing of Fc γ RIIb expression was found to eliminate A β signaling.

TABLE 1

RNA oligonucleotides for siRNA construction		
	Sequence	SEQ ID No.
siFcRb-5'-sense oligomer	5'-GATCCCTCGGAGAGCCACTTATGCTTTTCAAGAGAAGCATAAGTGGCTCTCCGATTTTGGAAA-3'	11
siFcRb-3'-antisense oligomer	5'-AGCTTTTCCAAAAATCGGAGAGCCACTTATGCTTCTCTTGAAGCATAAGTGGCTCTCCGAGAGTCGGG-3'	12

TABLE 1-continued

RNA oligonucleotides for siRNA construction		
	Sequence	SEQ ID No.
siRAGE-5'-sense oligomer	5'-GATCCCGCTCCGGATGAAGAATCAGTTC AAGAGACTGATTCTTCATCCGGAGCTTTT TGGAAA-3'	13
siRAGE-3'-sense oligomer	5'-AGCTTTTCCAAAAGCTCCGGATGAAGAA TCAGTCTCTTGAAGTATTCTTCATCCGG AGCGGAGTCGGG-3'	14

EXAMPLE 5

The Effect of FcγRIIb Extracellular Domain (ED) on Neuronal Cell Death

An FcγRIIb extracellular domain (ED) was purified as described in Sondermann et al., *EMBO J*, 18:1095-1103, 1999. Neuronal B103 cells or primary-cultured neuronal cells were exposed to 5 μM of Aβ for 48 hrs. Then, cells were treated or not treated with 100 μg of the purified FcγRIIb ED, or treated or not treated with 100 μg of bovine serum albumin (BSA). B103 cells were subjected to Western blotting, which was performed with anti-FcγRIIb antibody as described in Example 2-2. The primary neuronal culture was evaluated for cell survival as described in Example 3.

Compared to BSA treatment, the FcγRIIb ED was found to completely inhibit Aβ signaling in Aβ-exposed cells (FIG. 4), indicating that the FcγRIIb ED is an extracellular receptor of Aβ. Thus, the FcγRIIb ED may have potential as a target for inhibiting the neurotoxic signaling initiated by Aβ.

EXAMPLE 6

Immunohistochemical Assay

The transgenic mouse used in this test was Tg2576 (18 to 24 months old, female), which contained the human APP695 with the double mutation Lys670→Asn and Met671→Leu (K670N, M671L), which was found in a large Swedish family suffering from the early onset of Alzheimer's disease (Hsiao et al., *Science*, 274:99-102, 1996). The mouse was anesthetized with 7% chloral hydrate, and perfused transcardially with 4% phosphate-buffered paraformaldehyde (PFA; Sigma, USA). For neuropathological analysis, the brain was excised and immersed in PFA for 48 hrs. Then, the brain was cut into serial coronal sections on a freezing microtome. The sections were mounted on glass slides, dried, and fixed again with 4% PFA for 15 min. The sections were incubated in methanol, containing 3% H₂O₂ for 5 min, to remove endogenous peroxidase activity. Then, the brain sections were washed, immersed in 0.5% Triton X-100 for 30 min before being reacted with the primary antibody, and incubated with 1% bovine serum albumin for 1 hr.

Specimens from fifteen patients neuropathologically diagnosed as having AD (71 to 93 years of age; 83.83 years old on average; corpse dissection 2 to 16 hrs after death) were donated from McLean Hospital (Harvard Brain Tissue Resource Center, Belmont, Mass.) and Ohio state university (Columbus, Ohio). All tissues were confirmed through clinical records and neuropathological examinations.

Mouse brain sections and immunofluorescent-labeled brain sections from AD patients were observed under a fluorescence microscope (Leica DMRBE, Germany). Subsequently, brain sections were stained with an alkaline Congo red solution (Sigma, USA). Tg2576 mouse samples were stained with anti-oligo-Aβ antibody (Biosource, USA), NeuN (Chemicon, USA), and anti-FcγRIIb antibody (K9.361, gift from Dr. Hammerling, Memorial Sloan Kettering Cancer Center, NY; or rabbit polyclonal Antibody, gift from Dr. Cambier, University of Colorado Health Sciences Center, CO). AD patient samples were stained with anti-Aβ monoclonal antibody (4G8:Signet, USA), anti-PHF-1 antibody (gift from Dr. Davis, Albert Einstein College of Medicine, NY).

Both amyloid plaques (asterisk) and FcγRIIb immunoreactivity (arrowheads) were detected in the brains of AD patients. Also, strong immunoreactivity was observed within neuronal cells (right panels (b), FIG. 5). FcγRIIb was found to be strongly accumulated within neuronal cells and localized along with oligo-Aβ (FIG. 5). The strong increase of FcγRIIb in AD patients may be used in AD diagnosis. Also, these results demonstrate that FcγRIIb contributes to intraneuronal Aβ accumulation, indicating that FcγRIIb contributes to the intraneuronal accumulation of Aβ as well as the signaling ability of Aβ.

EXAMPLE 7

Evaluation of Intracellular Aβ Accumulation in B103 Cells Transfected with siRNA Expression Vectors

psiFcγRIIb #1 cells or psiRAGE #1 cells, prepared in Example 4, were exposed to 100 nM of Aβ or PBS for 12 hrs, and immunostained with anti-Aβ antibody (4G8; Signet, USA) according to the same method as in Example 2-3.

Intracellular Aβ accumulation was strongly inhibited in psiFcγRIIb cells but was maintained in psiRAGE cells, indicating that FcγRIIb mediates the intracellular accumulation of Aβ in neurons (FIG. 6). Thus, psiFcγRIIb of FcγRIIb mutants may be useful in inhibiting intraneuronal Aβ accumulation.

EXAMPLE 8

In Vitro Assay for the Binding Between FcγRII and Aβ₁₋₄₂

5 μM of Aβ was mixed with 20 μg of FcγRIIb-ED or 20 μg of BSA in vitro, and was incubated at 37° C. for 3 hrs. The reaction mixture was incubated with anti-FcγRIIb polyclonal antibody or anti-GST antibody for 2 hrs, and then with Protein G for 3 hrs (binding solution: 50 mM Tris-HCl, pH 7.4, 1 mM DTT, 0.5 mM EDTA, 0.01% Triton X-100, 0.5 mg/ml bovine serum albumin, 10% (v/v) glycerol, protease inhibitors cocktail, several concentrations of NP-40). The beads were washed three times and subjected to Western blotting to assess the association between FcγRII and Aβ₁₋₄₂. Western blotting was carried out with K9.361 antibody and anti-Aβ antibody (primary antibody: 71-5800 (Zymed, USA); secondary antibody: goat anti-rabbit IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA).

Aβ was found to directly bind to FcγRIIb-ED (FIG. 7). These results indicate that FcγRIIb is a receptor of Aβ and is thus useful in analysis for extracting inhibitors of the binding.

17

EXAMPLE 9

Evaluation of the Binding Between FcγRIIb-CD40 Chimera and Aβ

In order to investigate whether FcγRIIb binds to Aβ in a specific manner, an extracellular domain of FcγRIIb was genetically fused to CD40, consisting of a transmembrane domain and a cytoplasmic domain. The resulting FcγRIIb-CD40 fusion gene was expressed in NIH3T3 cells to increase NF-κ B activity, a signal transducer of CD40, when the fusion protein binds to Aβ. The chimeric gene was constructed as follows. A rat FcγRIIb extracellular region and human CD40 transmembrane and cytoplasmic domains were amplified by performing PCR with FcγRIIb-ED-5'-NheI primer (5'-GCTAGCGCTATGGACAGCAACAGGACT-3'; SEQ ID No. 15), FcγRIIb-ED-3'-HindIII primer (5'-AAGCTTGGGAGGCAACGAACTGCTGGATT3'; SEQ ID No. 16), CD40-TM+cyto-5' primer (5'-CCCAAGCTTGGGGC-CCTGGTGGTGTATCCCCATC-3'; SEQ ID No. 17), and CD40-TM+cyto-3' primer (5'-CGGGTACCATTCACTGTCTCTCCTGCAC-3'; SEQ ID No. 18). PCR products were inserted into a pEGFP-N1 vector according to the same method as in Example 3. Cells were transfected with the chimeric gene, CD40, TNFRI, pcDNA3 (mock) along with an NF-κB-luciferase gene, and were exposed to 5 μM of Aβ or 20 ng/ml of TNF. NF-κ B activity was assessed, as described in Woo et al., *FEBS Lett.* 578, 239-244, 2004.

When cells were exposed to Aβ, CD40 did not stimulate NF-κ B activity, but FcγRIIb-CD40 strongly stimulated NF-κ B activity (FIG. 8). These results indicate that Aβ binds specifically to FcγRIIb to form a complex, which is capable of triggering signal transduction.

EXAMPLE 10

Prediction of the Binding Structure of FcγRIIb and Aβ

In recent years, it has become apparent that Aβ accumulated in an irregularly aggregated form or in a fibrillar form does not cause signal transduction of neurotoxicity, but soluble oligomers of five or six Aβ monomers initiate neurotoxic signaling and stimulate memory decline (Cleary, J. P. et al. *Nat. Neurosci.* 8:79-84, 2005). The Aβ monomer is difficult to crystallize, and structure thereof is difficult to determine, due to its tendency to aggregate. For this reason, the structure of soluble oligomeric Aβ was predicted through computational analysis. A computational study revealed the assembly of Aβ monomers into a globular soluble oligomeric structure, in which N-terminal tails are exposed to the exterior and C-terminal hydrophobic regions aggregate to form an oligomer (Urbanc, B. et al. *Proc. Natl. Acad. Sci. U.S.A.* 101:17345-17350, 2004). Also, the N-terminal structure of oligomers was similar to that of monomeric Aβ. In this regard, the inventors of this application predicted that FcγRIIb binds the N-terminal region of Aβ, and identified first the binding site structures between FcγRIIb and Aβ using the N-terminal structure of Aβ, which was determined through a nuclear magnetic resonance (NMR) study of a computational prediction method (AffinityR program: InsightII, Accelrys Inc). The structures of the binding regions in FcγRIIb and Aβ were determined using a known crystal structure of FcγRIIb (Sondermann, P et al., *EMBO J.* 18:1095-1103, 1999). When a tryptophan residue critical for the binding of FcγRIIb to IgG was replaced with alanine, FcγRIIb showed remarkably reduced binding affinity to Aβ. Thus, the structure prediction

18

was carried out by placing the N-terminal region of Aβ proximate into a tryptophan pocket of FcγRIIb.

In detail, in silico analysis was performed using the crystal structure of human FcγRIIb extracellular domain (PDB code: 2FCB, RCSB) and the NMR structure of Aβ₁₋₄₂ (PDB code: 1IYT, RCSB). Using Affinity program within InsightII (Accelrys), the N-terminal region of Aβ₁₋₄₂ was docked with the IgG binding site of FcγRIIb. The binding site was defined as an 8-Å radius from Trp92 and Trp115 residues of human FcγRIIb (hFcγRIIb). Aβ₁₋₄₂ Phe4 was first artificially located closed to Trp92 and Trp115 residues of hFcγRIIb, and the general binding procedure was then performed as follows. Molecular dynamic calculations for the binding between hFcγRIIb and Aβ were carried out using the CUFF force field. The initial structure was generated using a Monte Carlo minimization method, and simulated to generate actual non-bond contacts using a Cell Multipole method. Such simulated annealing started at 500 K, and the temperature was slowly cooled down to 300 K for stabilization through over 50 steps, followed by a final round of over 1000 steps of energy minimization for final structure calculation.

The structure calculations revealed that in a manner similar to that in which a proline residue of IgG is critical for FcγRIIb binding, the fourth residue phenylalanine of Aβ forms a strong hydrophobic bond with Trp92 and Trp115 of FcγRIIb. In contrast, the third residue glutamate of Aβ formed a relatively weak hydrophilic bond with Tyr165 of FcγRIIb. However, the fifth and sixth residues (Arg5, His6) of Aβ were not involved in FcγRIIb binding. Thus, the binding of Aβ to FcγRIIb was predicted to occur through the binding of a sequence stretch consisting of the third to seventh residues from the N-terminus of Aβ to a tryptophan pocket and Tyr165 of FcγRIIb (FIG. 9). These results indicated that Aβ signaling can be inhibited by interrupting the binding thereof to FcγRIIb.

EXAMPLE 11

Interruption of the Binding Between FcγRIIb and Aβ

Based on the results of Example 10, a sequence spanning from the first to ninth residues from the N-terminus of Aβ, and a 95 to 101 sequence and a 107 to 114 sequence of mouse FcγRIIb, which are Aβ docking sites, were synthesized. Also, peptides, in which a residue involved in Aβ-cγRIIb binding in the above sequences was replaced with alanine, were synthesized. The peptides (wild type and mutant) have the sequences represented by SEQ ID Nos. 19 to 28 (panel a, FIG. 10). The synthesized peptides were individually allowed to react with a mixture of FcγRIIb-CD40 and Aβ (5 μM) or PBS. Then, luciferase activity was measured.

The NF-κ B activation, induced through the binding of Aβ to FcγRIIb-CD40, was strongly inhibited by peptides #1, #4 and #9, which corresponded to binding regions in Aβ and FcγRIIb. Mutant peptides #2, #3, #6, #7 and #10, having an alanine substitution for a residue responsible for Aβ-cγRIIb binding, exhibited a sharp decrease in inhibitory effects on NF-κ B activation (panel b, FIG. 10). These results indicated that the binding structure of Aβ and cγRIIb (FIG. 9), determined in Example 9, is actually important in Aβ-cγRIIb binding, and that the above peptides have the potential to inhibit Aβ signaling.

EXAMPLE 12

Inhibition of Aβ-Induced Neurotoxicity Using the Peptides Inhibiting FcγRIIb-Aβ Binding

Primary neuronal cells were treated with the peptides (15 μM each) prepared in Example 11 and Aβ (5 μM) for 48 hrs.

19

Relative cell survival rates were then measured and compared with a control. Among rat primary neuronal cells, hippocampal neurons were treated with peptides #1 to #7, and rat cortical neurons were treated with peptides #8 to #10.

The binding inhibitory peptides were found to inhibit the neuronal toxicity induced by A β through its binding to Fc γ RIIb (FIG. 11). Thus, since the peptides are able to strongly inhibit the neurotoxic signaling of A β , they may be useful in the prevention and treatment of AD.

EXAMPLE 13

Memory Test

Tg2576 mice were not used in this test because it takes a lot of time to breed the animals, and they are expensive. Instead, normal mice were used in this memory test because the same AD symptoms as in Tg2576 mice were observed when A β was injected into the brains of normal mice. Normal BALB/c mice were injected intracerebroventricularly (i.c.v.) with A β (1.855 μ g/5 μ l, 410 pmole) alone or in combination with a specific peptide. After one day, a Y-maze test and a passive avoidance test were performed. Memory was assessed as described in Yan et al., *Br. J. Pharmacol.*, 133:89-96, 2001.

When mice received i.c.v. injection of A β and a peptide, peptide #1 or #9, inhibiting Fc γ RIIb-A β binding, were found to strongly reduce A β -induced memory decline, whereas a mutant peptide #7 failed to reverse memory decline (FIG. 12). Thus, peptides #1 and #9 may be effective in the prevention and treatment of AD.

EXAMPLE 14

Evaluation of In Vivo Effects of the Binding Inhibitory Peptides

Brain specimens were prepared from the mice of Example 13 according to the same method as in Example 6. Sections

20

were immunostained with primary antibodies, anti-A β antibody (Biosource, USA) plus an antibody to a marker of neurons, anti-neuron specific enolase (NSE) antibody (Axxora, Swiss) or anti-neuron specific nuclear protein (NeuN) antibody (Chemicon, USA), and with secondary antibodies, anti-mouse-FITC antibody (goat anti-mouse IgG conjugated to FITC (Santa Cruz Biotechnology, USA), anti-mouse-TRITC antibody (goat anti-mouse IgG conjugated to TRITC (Santa Cruz Biotechnology, USA), and anti-rabbit-goat-anti-mouse IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology, USA)).

Strong accumulation of intraneuronal A β was observed in mice treated with A β alone, but this phenomenon disappeared in mice treated with A β plus binding inhibitory peptide #1. In contrast, a strong intraneuronal A β staining was observed in mice treated with A β plus peptide #7, found not to have inhibitory capacity against A β -Fc γ RIIb binding (FIG. 13). These results indicate that the binding inhibitory peptide also effectively inhibits the binding between A β and Fc γ RIIb in vivo, and is thus useful as an effective therapeutic and preventive agent for AD.

In accordance with the present invention, as described above, an the interaction inhibitor is provided for effectively inhibiting the binding of A β to Fc γ RIIb in neuronal cells and an animal model of Alzheimer's disease, thereby reducing A β -induced neurotoxicity and cell death therein. Thus, the present inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.

Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 32

<210> SEQ ID NO 1

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma receptor I Ib-5-EcoRI

<400> SEQUENCE: 1

cgcggaattc gatggacagc aacaggact

29

<210> SEQ ID NO 2

<211> LENGTH: 28

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma receptor I Ib-3-KpnI

<400> SEQUENCE: 2

cgggtaccat aatgtggttc tggtagtc

28

<210> SEQ ID NO 3

<211> LENGTH: 40

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor I-RT-5

<400> SEQUENCE: 3

ttggtgaaca cagttctcta tgtgaaaata cacaggctgc 40

<210> SEQ ID NO 4
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor I-RT-3

<400> SEQUENCE: 4

ctatcttaca gtggctgtta cttcttcata cacgtcatcg ct 42

<210> SEQ ID NO 5
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor IIa-RT-5

<400> SEQUENCE: 5

gccgatttct gcctagtgat gtgcctcctg tttgcagtgg 40

<210> SEQ ID NO 6
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor IIa-RT-3

<400> SEQUENCE: 6

tcatttgtcc tgtggagcct ctttccgact gacagggatc 40

<210> SEQ ID NO 7
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer for beta
actin-5 for RT-PCR

<400> SEQUENCE: 7

gcgtccaccc gcgag 15

<210> SEQ ID NO 8
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer for beta
actin-3 for RT-PCR

<400> SEQUENCE: 8

tatagcaggg tcaac 15

<210> SEQ ID NO 9
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<210> SEQ ID NO 15
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor IIb-ED-5-NheI

<400> SEQUENCE: 15

gctagcgcta tggacagcaa caggact 27

<210> SEQ ID NO 16
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer Fc gamma
receptor IIb-ED-3-HindIII

<400> SEQUENCE: 16

aagcttgga ggcaacgaac tctggattt 30

<210> SEQ ID NO 17
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer
CD40-TM+cyto-5-HindIII

<400> SEQUENCE: 17

cccaagcttg gggccctggt ggtgatcccc atc 33

<210> SEQ ID NO 18
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide primer
CD40-TM+cyto-3-KpnI

<400> SEQUENCE: 18

cgggtacat tcaactgtctc tcctgcac 28

<210> SEQ ID NO 19
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #1 for interaction inhibitor

<400> SEQUENCE: 19

Asp Ala Glu Phe Arg His Asp Ser Gly
1 5

<210> SEQ ID NO 20
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #2 for interaction inhibitor

<400> SEQUENCE: 20

Asp Ala Ala Phe Arg His Asp Ser Gly
1 5

-continued

<210> SEQ ID NO 21
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #3 for interaction inhibitor

<400> SEQUENCE: 21

Asp Ala Glu Ala Arg His Asp Ser Gly
1 5

<210> SEQ ID NO 22
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #4 for interaction inhibitor

<400> SEQUENCE: 22

Asp Ala Glu Phe Ala His Asp Ser Gly
1 5

<210> SEQ ID NO 23
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #5 for interaction inhibitor

<400> SEQUENCE: 23

Asp Ala Glu Phe Arg Ala Asp Ser Gly
1 5

<210> SEQ ID NO 24
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #6 for interaction inhibitor

<400> SEQUENCE: 24

Asp Ala Glu Phe Arg His Ala Ser Gly
1 5

<210> SEQ ID NO 25
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #7 for interaction inhibitor

<400> SEQUENCE: 25

Asp Ala Glu Ala Arg His Ala Ser Gly
1 5

<210> SEQ ID NO 26
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic peptide #8 for interaction inhibitor

<400> SEQUENCE: 26

Gln Leu Val Phe Leu Glu Gly
1 5

-continued

<210> SEQ ID NO 27
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide #9 for interaction inhibitor

<400> SEQUENCE: 27

Arg Cys His Ser Trp Arg Asn Lys
 1 5

<210> SEQ ID NO 28
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic peptide #10 for interaction inhibitor

<400> SEQUENCE: 28

Arg Cys His Ser Ala Arg Asn Lys
 1 5

<210> SEQ ID NO 29
 <211> LENGTH: 43
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Amyloid beta peptide

<400> SEQUENCE: 29

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1 5 10 15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
 20 25 30

Gly Leu Met Val Gly Gly Val Ile Ala Thr
 35 40

<210> SEQ ID NO 30
 <211> LENGTH: 1633
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: human Fc gamma receptor IIb DNA sequence

<400> SEQUENCE: 30

agaatttggtt tgccctctag ggtagaatcc gccaaagcttt gagagaaggc tgtgactgct	60
gtgctctggg cgccagctcg ctccaggag tgatgggaat cctgtcatc ttacctgtcc	120
ttgccactga gagtgactgg gctgactgca agtccccca gccttggggg catatgcttc	180
tgtggacagc tgtgctatc ctggctcctg ttgctgggac acctgcagct cccccaaagg	240
ctgtgctgaa actcgagccc cagtggatca acgtgctcca ggaggactct gtgactctga	300
catgccgggg gactcacagc cctgagagcg actccattca gtggttccac aatgggaatc	360
tcattccac ccacacgcag cccagctaca ggttcaaggc caacaacaat gacagcgggg	420
agtacacgtg ccagactggc cagaccagcc tcagegacct tgtgcactg actgtgcttt	480
ctgagtggct ggtgctccag acccctcacc tggagtcca ggaggagaa accatcgtgc	540
tgaggtgcc cagctggaag gacaagcctc tgggtcaagg caccattctc cagaatggaa	600
aatccaagaa attttccgt tcggatccca acttctccat cccacaagca aaccacagtc	660
acagtgtga ttaccactgc acaggaaaca taggctacac gctgtactca tccaagcctg	720
tgaccatcac tgtccaagct cccagctctt caccgatggg gatcattgtg gctgtgggtca	780

-continued

```

ctgggattgc tgtageggcc attgttgctg ctgtagtggc cttgatctac tgcaggaaaa   840
agcggatttc agctctccca ggataccctg agtgcaggga aatgggagag accctccctg   900
agaaaccagc caatcccact aatcctgatg aggctgacaa agttggggct gagaacacaa   960
tcacctattc acttctcatg caccgggatg ctctggaaga gcctgatgac cagaaccgta  1020
tttagtctcc attgtcttgc attgggattt gagaagaaaa tcagagaggg aagatctggt  1080
atttcctggc ctaaatcccc cttggggagg acagggagat gctgcagttc caaaagagaa  1140
ggtttcttcc agagtcatct acctgagtcc tgaagctccc tgtcctgaaa gccacagaca  1200
atatgggtccc aaatgaccga ctgcaccttc tgtgcttcag ctcttcttga catcaaggct  1260
cttcctgtcc acatccacac agccaatcca attaatcaaa cactgttat taacagataa  1320
tagcaacttg ggaaatgctt atgttacagg ttacgtgaga acaatcatgt aaatctatat  1380
gatttcagaa atgttaaaat agactaacct ctaccagcac attaaaagtg attgtttctg  1440
ggtgataaaa ttattgatga tttttatttt cttttatttt ctataaagat catatattac  1500
ttttataata aaacattata aaaacaacat tctgtttacc ttttcaaggc tgtattgggt  1560
ggagtgtaga ctgaactgcc tggggctctgt ttctcttcag tgatgagact cttaggaagg  1620
caggaatgga tag                                     1633

```

```

<210> SEQ ID NO 31
<211> LENGTH: 310
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: human Fc gamma receptor IIb amino acid sequence

<400> SEQUENCE: 31

```

```

Met Gly Ile Leu Ser Phe Leu Pro Val Leu Ala Thr Glu Ser Asp Trp
1           5           10           15

Ala Asp Cys Lys Ser Pro Gln Pro Trp Gly His Met Leu Leu Trp Thr
20          25          30

Ala Val Leu Phe Leu Ala Pro Val Ala Gly Thr Pro Ala Ala Pro Pro
35          40          45

Lys Ala Val Leu Lys Leu Glu Pro Gln Trp Ile Asn Val Leu Gln Glu
50          55          60

Asp Ser Val Thr Leu Thr Cys Arg Gly Thr His Ser Pro Glu Ser Asp
65          70          75          80

Ser Ile Gln Trp Phe His Asn Gly Asn Leu Ile Pro Thr His Thr Gln
85          90          95

Pro Ser Tyr Arg Phe Lys Ala Asn Asn Asn Asp Ser Gly Glu Tyr Thr
100         105         110

Cys Gln Thr Gly Gln Thr Ser Leu Ser Asp Pro Val His Leu Thr Val
115         120         125

Leu Ser Glu Trp Leu Val Leu Gln Thr Pro His Leu Glu Phe Gln Glu
130         135         140

Gly Glu Thr Ile Val Leu Arg Cys His Ser Trp Lys Asp Lys Pro Leu
145         150         155         160

Val Lys Val Thr Phe Phe Gln Asn Gly Lys Ser Lys Lys Phe Ser Arg
165         170         175

Ser Asp Pro Asn Phe Ser Ile Pro Gln Ala Asn His Ser His Ser Gly
180         185         190

Asp Tyr His Cys Thr Gly Asn Ile Gly Tyr Thr Leu Tyr Ser Ser Lys
195         200         205

```

-continued

```

Pro Val Thr Ile Thr Val Gln Ala Pro Ser Ser Ser Pro Met Gly Ile
 210                215                220

Ile Val Ala Val Val Thr Gly Ile Ala Val Ala Ala Ile Val Ala Ala
 225                230                235                240

Val Val Ala Leu Ile Tyr Cys Arg Lys Lys Arg Ile Ser Ala Leu Pro
      245                250                255

Gly Tyr Pro Glu Cys Arg Glu Met Gly Glu Thr Leu Pro Glu Lys Pro
      260                265                270

Ala Asn Pro Thr Asn Pro Asp Glu Ala Asp Lys Val Gly Ala Glu Asn
      275                280                285

Thr Ile Thr Tyr Ser Leu Leu Met His Pro Asp Ala Leu Glu Glu Pro
 290                295                300

Asp Asp Gln Asn Arg Ile
305                310

```

```

<210> SEQ ID NO 32
<211> LENGTH: 310
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: human Fc gamma receptor IIb[I232T] mutant amino
      acid sequence

```

```

<400> SEQUENCE: 32

```

```

Met Gly Ile Leu Ser Phe Leu Pro Val Leu Ala Thr Glu Ser Asp Trp
 1                5                10                15

Ala Asp Cys Lys Ser Pro Gln Pro Trp Gly His Met Leu Leu Trp Thr
      20                25                30

Ala Val Leu Phe Leu Ala Pro Val Ala Gly Thr Pro Ala Ala Pro Pro
      35                40                45

Lys Ala Val Leu Lys Leu Glu Pro Gln Trp Ile Asn Val Leu Gln Glu
 50                55                60

Asp Ser Val Thr Leu Thr Cys Arg Gly Thr His Ser Pro Glu Ser Asp
 65                70                75                80

Ser Ile Gln Trp Phe His Asn Gly Asn Leu Ile Pro Thr His Thr Gln
      85                90                95

Pro Ser Tyr Arg Phe Lys Ala Asn Asn Asn Asp Ser Gly Glu Tyr Thr
      100                105                110

Cys Gln Thr Gly Gln Thr Ser Leu Ser Asp Pro Val His Leu Thr Val
      115                120                125

Leu Ser Glu Trp Leu Val Leu Gln Thr Pro His Leu Glu Phe Gln Glu
      130                135                140

Gly Glu Thr Ile Val Leu Arg Cys His Ser Trp Lys Asp Lys Pro Leu
      145                150                155                160

Val Lys Val Thr Phe Phe Gln Asn Gly Lys Ser Lys Lys Phe Ser Arg
      165                170                175

Ser Asp Pro Asn Phe Ser Ile Pro Gln Ala Asn His Ser His Ser Gly
      180                185                190

Asp Tyr His Cys Thr Gly Asn Ile Gly Tyr Thr Leu Tyr Ser Ser Lys
      195                200                205

Pro Val Thr Ile Thr Val Gln Ala Pro Ser Ser Ser Pro Met Gly Ile
      210                215                220

Ile Val Ala Val Val Thr Gly Thr Ala Val Ala Ala Ile Val Ala Ala
      225                230                235                240

Val Val Ala Leu Ile Tyr Cys Arg Lys Lys Arg Ile Ser Ala Leu Pro

```

-continued

245							250					255				
Gly	Tyr	Pro	Glu	Cys	Arg	Glu	Met	Gly	Glu	Thr	Leu	Pro	Glu	Lys	Pro	
260							265					270				
Ala	Asn	Pro	Thr	Asn	Pro	Asp	Glu	Ala	Asp	Lys	Val	Gly	Ala	Glu	Asn	
275							280					285				
Thr	Ile	Thr	Tyr	Ser	Leu	Leu	Met	His	Pro	Asp	Ala	Leu	Glu	Glu	Pro	
290							295					300				
Asp	Asp	Gln	Asn	Arg	Ile											
305							310									

What is claimed is:

1. A method of treating Alzheimer's disease in a subject comprising administering to the subject an agent inhibiting interaction between amyloid- β ($A\beta$) and Fc γ receptor IIb (Fc γ RIIb), wherein the agent inhibiting interaction between

¹⁵ $A\beta$ and Fc γ RIIb is a peptide consisting of the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 27, and wherein the peptide is administered to the subject by intracerebroven-tricular injection.

* * * * *